| Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial | Lancet, The | 2016 | 428 |
| Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors | Cancer Discovery | 2016 | 397 |
| TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques | Journal of Experimental Medicine | 2016 | 367 |
| Histone Modifications and Cancer | Cold Spring Harbor Perspectives in Biology | 2016 | 328 |
| Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages | Brain | 2016 | 275 |
| Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients | Alzheimer's and Dementia | 2016 | 241 |
| Drug development in Alzheimer's disease: the path to 2025 | Alzheimer's Research and Therapy | 2016 | 234 |
| TREM2 variants: new keys to decipher Alzheimer disease pathogenesis | Nature Reviews Neuroscience | 2016 | 220 |
| Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer | Cancer Treatment Reviews | 2016 | 213 |
| Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor | Biological Psychiatry | 2016 | 211 |
| An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation | Genome Biology | 2016 | 189 |
| Photochemical Perfluoroalkylation with Pyridine -Oxides: Mechanistic Insights and Performance on a Kilogram Scale | CheM | 2016 | 170 |
| Biased agonism: An emerging paradigm in GPCR drug discovery | Bioorganic and Medicinal Chemistry Letters | 2016 | 167 |
| Clinical development of new drug-radiotherapy combinations | Nature Reviews Clinical Oncology | 2016 | 162 |
| High-Fat Diet Induced Anxiety and Anhedonia: Impact on Brain Homeostasis and Inflammation | Neuropsychopharmacology | 2016 | 159 |
| Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults | JAMA Neurology | 2016 | 157 |
| A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis | British Journal of Dermatology | 2016 | 156 |
| Direct in vivo evidence of activated macrophages in human osteoarthritis | Osteoarthritis and Cartilage | 2016 | 142 |
| The next generation of therapeutics for chronic kidney disease | Nature Reviews Drug Discovery | 2016 | 140 |
| Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study | Annals of the Rheumatic Diseases | 2016 | 139 |
| Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study | Annals of the Rheumatic Diseases | 2016 | 138 |
| Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays | Clinical Chemistry | 2016 | 135 |
| Can computed crystal energy landscapes help understand pharmaceutical solids? | Chemical Communications | 2016 | 116 |
| Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A | Journal of Inflammation Research | 2016 | 115 |
| Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies | Diabetes Care | 2016 | 113 |
